Suppr超能文献

十二指肠胃肠道间质瘤(GIST)治疗中的手术方法与肿瘤学结局

Surgical Approaches and Oncological Outcomes in the Management of Duodenal Gastrointestinal Stromal Tumors (GIST).

作者信息

Vassos Nikolaos, Perrakis Aristotelis, Hohenberger Werner, Croner Roland S

机构信息

Division of Surgical Oncology, Department of Surgery, Mannheim University Medical Center, University of Heidelberg, 68167 Mannheim, Germany.

Department of Surgery, University Hospital Erlangen, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.

出版信息

J Clin Med. 2021 Sep 28;10(19):4459. doi: 10.3390/jcm10194459.

Abstract

BACKGROUND

Duodenal gastrointestinal stromal tumors (GIST) are a rare subset of GIST. Their surgical management in this anatomically complex region consists of varied approaches, and the administration of imatinib mesylate (IM) has not been clarified.

METHODS

We retrospectively reviewed patients with duodenal GIST treated during a 10-year-period. We analysed the clinicopathological characteristics and survival factors and evaluated the perioperative and long-term outcomes based on the extent of resection ((ocal-resection (LR) versus pancreaticoduodenectomy (PD)) and the IM-administration. The median follow-up period was 60 months (range, 12-140).

RESULTS

A total of thirteen patients (M:F = 7:6) with median age of 64 years (range, 42-77) underwent resection of duodenal GIST. Median tumor size was 5.2 cm (range, 1.5-13.3). Eight patients (61.5%) underwent LR and five patients (38.5%) PD. R0-resection was achieved in 92.5%. Neoadjuvant IM-therapy was administered in five patients leading to tumor downsizing and in 40% to less-extended resection. The PD group consisted of larger tumors with higher mitotic count, mostly located in D2 ( = 0.031). The PD group had longer operative time ( = 0.026), longer hospital stay ( = 0.016), and higher rate of postoperative complications ( = 0.128). The actuarial 1-, 3-, and 5-year overall survival were 92.5%, 84%, and 73.5%, respectively, whereas the disease-free survival rates at 1, 3, and 5 years were 91.5%, 83%, and 72%, respectively. A tendency towards increased risk of disease recurrence was demonstrated for patients with tumor >5 cm and high-risk potential. There was not statistic survival benefit for one or the other surgical approach.

CONCLUSION

The type of resection depends on duodenal site of origin and tumor size. LR can be the treatment of choice for duodenal GIST whenever technically feasible. Recurrence of duodenal GIST is dependent on tumor biology rather than surgical approach. Administration of IM in neaodjuvant setting should be considered in cases with high-risk GIST scheduled for PD since it might facilitate less-extended resection.

摘要

背景

十二指肠胃肠道间质瘤(GIST)是GIST的一个罕见亚型。在这个解剖结构复杂的区域,其手术治疗方法多样,而甲磺酸伊马替尼(IM)的应用尚不明确。

方法

我们回顾性分析了10年间接受治疗的十二指肠GIST患者。我们分析了临床病理特征和生存因素,并根据切除范围(局部切除(LR)与胰十二指肠切除术(PD))和IM的应用评估了围手术期和长期结局。中位随访期为60个月(范围12 - 140个月)。

结果

共有13例患者(男:女 = 7:6)接受了十二指肠GIST切除术,中位年龄64岁(范围42 - 77岁)。中位肿瘤大小为5.2 cm(范围1.5 - 13.3 cm)。8例患者(61.5%)接受了LR,5例患者(38.5%)接受了PD。R0切除率为92.5%。5例患者接受了新辅助IM治疗,导致肿瘤缩小,40%的患者得以进行范围较小的切除。PD组肿瘤较大,有丝分裂计数较高,大多位于D2段(P = 0.031)。PD组手术时间更长(P = 0.026),住院时间更长(P = 0.016),术后并发症发生率更高(P = 0.128)。1年、3年和5年的精算总生存率分别为92.5%、84%和73.5%,而1年、3年和5年的无病生存率分别为91.5%、83%和72%。肿瘤>5 cm且具有高风险潜能的患者显示出疾病复发风险增加的趋势。两种手术方式在生存方面均无统计学显著获益。

结论

切除方式取决于十二指肠的起源部位和肿瘤大小。只要技术可行,LR可作为十二指肠GIST的首选治疗方法。十二指肠GIST的复发取决于肿瘤生物学特性而非手术方式。对于计划接受PD的高危GIST患者,应考虑在新辅助治疗中应用IM,因为这可能有助于进行范围较小的切除。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cad/8509470/968ddb531b6c/jcm-10-04459-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验